VINC

Vincerx Pharma, Inc. Common Stock

VINC, USA

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.

https://vincerx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VINC
stock
VINC

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders The Manila Times

Read more →
VINC
stock
VINC

VINC stock touches 52-week low at $0.17 amid sharp annual decline Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-03-31)

Rating:

STRONG BUY

Target Price:

$200

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-03-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.03

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-242.01 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-106.70 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.27

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.08% of the total shares of Vincerx Pharma, Inc. Common Stock

1.

Fidelity Series Total Market Index

(0.0433%)

since

2025/07/31

2.

Fidelity Total Market Index

(0.0296%)

since

2025/07/31

3.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0035%)

since

2024/12/31

4.

SSgA U.S. Total Market Index Strategy

(0.0016%)

since

2025/03/31

5.

Bank & Trust Co

(0.001%)

since

2025/06/30

6.

Fidelity U.S. Equity Index Ins Trust

(0.0002%)

since

2025/07/31

7.

Goldman Sachs Group Inc

(0%)

since

2025/06/30

8.

State Street Corp

(0%)

since

2025/03/31

11.

BlackRock Inc

(0%)

since

2025/06/30

12.

Jane Street Group LLC

(0%)

since

2025/03/31

13.

Tower Research Capital LLC

(0%)

since

2025/06/30

14.

Northern Trust Corp

(0%)

since

2025/03/31

15.

Citadel Advisors Llc

(0%)

since

2025/06/30

16.

UBS Group AG

(0%)

since

2025/06/30

17.

Millennium Management LLC

(0%)

since

2025/06/30

18.

SAGE RHINO CAPITAL LLC

(0%)

since

2025/06/30

19.

Renaissance Technologies Corp

(0%)

since

2025/03/31

21.

Vanguard Group Inc

(0%)

since

2025/06/30

22.

Geode Capital Management, LLC

(0%)

since

2025/06/30

23.

JPMorgan Chase & Co

(0%)

since

2025/06/30

24.

Armistice Capital, LLC

(0%)

since

2025/03/31

25.

SBI Securities Co Ltd

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-03-31

EPS Actual

-3.5694

EPS Estimate

-0.12

EPS Difference

-3.4494

Surprise Percent

-2874.5%

Investing Fit Scorecard

(Last Updated 2025-03-31)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2.5)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(1.5)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.